Adam Yopp
Professor of Surgery
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Study Outcomes. Studies grouped by survival, early stage at diagnosis and treatment type. Underline studies were used in analysis of ICC alone. Overall Survival (OS), Extrahepatic Cholangiocarcinoma (ECC), Surveillance, Epidemiology, and End Results (SEER), Memorial Sloan-Kettering (MSK), Texas Cancer Registry (TCR), National Cancer Database (NCDB), Indiana Cancer Registry (ICR), National Inpatient Sample (NIS), University of Michigan (UM) Queen’s Medical Center of Hawaii (HI)
Year:
2025
Background: Cholangiocarcinoma (CCA) is an increasing cause of mortality in the United States; however, the burden of CCA disproportionately affects racial and ethnic minority groups. We aimed to characterize racial and ethnic differences in stage, treatment, and survival among patients with CCA. Methods: We systematically searched MEDLINE and Embase through March 2023 for all studies reporting clinical outcomes among patients with CCA stratified by race and ethnicity. We calculated pooled HRs using the DerSimonian and Laird method for a random-effects model. Results: Of 292 articles, 16 met inclusion criteria ( n = 248,109 patients). Among six studies ( n = 87,938) reporting overall survival, Black patients had worse survival [pooled HR, 1.05; 95% confidence interval (CI), 1.01–1.10], whereas Hispanic (pooled HR, 0.86; 95% CI, 0.83–0.89) and Asian/Pacific Islander (pooled HR, 0.88; 95% CI, 0.85–0.90) patients had better survival than White patients. Compared with White patients, Black and Hispanic patients were less likely to present at an early stage, and Black patients were less likely to undergo resection (pooled OR, 0.69; 95% CI, 0.63–0.75). The limitations of studies were lack of granularity on subtype and risk of residual confounding. Conclusions: There are racial and ethnic differences in CCA prognosis in the United States, with Black patients having worse survival and Hispanic and Asian patients having better survival than White patients. Studies are needed to identify actionable factors underlying this disparity to promote health equity and improve outcomes for patients. Impact: There exist racial discrepancies in survival and treatment for CCA; more studies are needed to better understand the extent and causes of discrepancies.
Year:
2025
Flow diagram for study selection. Studies were identified through keyword search of MEDLINE and OVID, abstracts and full text were sequentially reviewed by two separate reviewers. Relevant articles were further reviewed to discard overlapping studies.
Year:
2025
Kartung-Knell-Sidik-Jonkmann Forest Plots. (A) Hazard Ratios (HRs) for overall survival comparing Black vs. White patients. (B) HRs for overall survival HRs comparing Hispanic vs. White patients. (C) HRs for overall survival comparing Asian vs. White patients. (D) Odds Rations (ORs) for surgical resection comparing Black vs. White patients.
Year:
2025
Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.
Year:
2025
Collaborators (16)
Zhikai Chi
University of Texas Southwestern Medical Center
Amit G. Singal
-
Cheryl Lewis
Associate Professor
University of Texas Southwestern
Todd Aguilera
University of Texas Southwestern Medical Center
John Mansour
Professor
University of Texas Southwestern Medical Center
Song Zhang
-
Matthew R. Porembka
University of Texas Southwestern Medical Center
Madhukar S. Patel
University of Texas Southwestern Medical Center
Ahmed M. Elamir
Assistant professor (tenure track)
East Carolina University
Gonzalo Sapisochin
University of Toronto
David Hsiehchen
University of Texas Southwestern Medical Center
Syed Kazmi
Assistant Professor
University of Texas Southwestern Medical Center
Nicole Rich
Assistant Professor
University of Texas Southwestern Medical Center
Patricio M. Polanco
Professor
-
Herbert Zeh
Chair of Surgery
University of Texas Southwestern Medical Center
Nina N Sanford
University of Texas Southwestern
Make your next move.
Prepare your application
Review drafts before you send them.